Joshua Bauml, MD, University of Pennsylvania

Articles by Joshua Bauml, MD, University of Pennsylvania

Optimizing Testing Strategies in Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

NTRK Fusions in Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

MET Exon 14 Mutations in Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

RET Fusions in Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

ROS1-Rearranged Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

Rebiopsy at Progression of ALK-Rearranged NSCLC

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

Treating ALK-Rearranged Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

Trials in ALK-Rearranged Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

KRAS Testing in Non¬–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

Trastuzumab Deruxtecan for HER2+ Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

Treating Non–Small Cell Lung Cancer With an EGFR Exon 20 Insertion

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

EGFR Exon 20 Mutations in Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

Chemotherapy-TKI Combinations in Metastatic EGFR+ Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

TKI Combinations in Metastatic EGFR+ Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

Role of Adjuvant Osimertinib in Early Stage NSCLC

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

ADAURA Trial; Early Stage Non–Small Cell Lung Cancer

ByBenjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center,Lyudmila A. Bazhenova, MD, University of California San Diego,Joshua Bauml, MD, University of Pennsylvania,Rebecca Heist, MD, Massachusetts General Hospital Cancer Center

August 10th 2020

Latest Updated Articles

RET Fusions in Non–Small Cell Lung Cancer
August 10th 2020
Trastuzumab Deruxtecan for HER2+ Non–Small Cell Lung Cancer
August 10th 2020
ROS1-Rearranged Non–Small Cell Lung Cancer
August 10th 2020
Role of Adjuvant Osimertinib in Early Stage NSCLC
August 10th 2020
Optimizing Testing Strategies in Non–Small Cell Lung Cancer
August 10th 2020
Treating Non–Small Cell Lung Cancer With an EGFR Exon 20 Insertion
August 10th 2020

Joshua Bauml, MD, University of Pennsylvania

Articles by Joshua Bauml, MD, University of Pennsylvania

Optimizing Testing Strategies in Non–Small Cell Lung Cancer

NTRK Fusions in Non–Small Cell Lung Cancer

MET Exon 14 Mutations in Non–Small Cell Lung Cancer

RET Fusions in Non–Small Cell Lung Cancer

ROS1-Rearranged Non–Small Cell Lung Cancer

Rebiopsy at Progression of ALK-Rearranged NSCLC

Treating ALK-Rearranged Non–Small Cell Lung Cancer

Trials in ALK-Rearranged Non–Small Cell Lung Cancer

KRAS Testing in Non¬–Small Cell Lung Cancer

Trastuzumab Deruxtecan for HER2+ Non–Small Cell Lung Cancer

Treating Non–Small Cell Lung Cancer With an EGFR Exon 20 Insertion

EGFR Exon 20 Mutations in Non–Small Cell Lung Cancer

Chemotherapy-TKI Combinations in Metastatic EGFR+ Lung Cancer

TKI Combinations in Metastatic EGFR+ Lung Cancer

Role of Adjuvant Osimertinib in Early Stage NSCLC

ADAURA Trial; Early Stage Non–Small Cell Lung Cancer

Latest Updated Articles

Trending on OncLive

ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC

Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL

Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC

Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg

HERTHENA-Breast04 Is Set to Delineate the Role of HER3-Targeted Therapy in Advanced HR+ Breast Cancer